EICHOR
● Recruiting
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients
Condition: LCA5 · Sponsor: Opus Genetics, Inc
About this study
The goals of this clinical trial are assess the natural course of LCA5-IRD over 6 months and to evaluate the safety and preliminary efficacy of subretinal gene therapy with OPGx-001 in patients with inherited retinal degeneration due to biallelic mutations in the LCA5 gene. Funding Source- FDA Office of Orphan Products Development (OOPD).
This description comes directly from the study's public registry record.
Talk to the study team
Tomas Aleman, M.D. · 1 (215) 662-6396 · ct.gov_inquiries@opusgtx.com
Mariejel Weber · 1 (215) 662-6396 · mariejel.weber@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
Locations (2)
| University of Pennsylvania Perelman School of Medicine | Philadelphia, Pennsylvania, United States | Recruiting |
| Retina Foundation of the Southwest | Dallas, Texas, United States | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05616793